Details for Patent: 5,053,432

Summary for Patent: 5,053,432

Title:	Naphthoquinone derivatives
Abstract:	Novel antiprotozoal naphthoquinones having the general formula ##STR1## (wherein either R1 is hydrogen and R2 is selected from C1-6 alkoxy, aralkoxy, C1-6 alkyl-C1-6 alkoxy, phenyl substituted by one or two groups selected from halogen and C1-6 alkyl, halogen and perhalo-C1-6 alkyl; or R1 and R2 are both C1-6 alkyl or phenyl; and n is 0 or 1) and salt thereof. The compounds of formula (I) are useful for the treatment or prophylaxis of protozoal diseases including malaria, theileriosis and coccidiosis. Various processes for preparing compounds of formula (I) are described.
Inventor(s):	Alan T. Hudson, Anthony W. Randall
Assignee:	SmithKline Beecham Corp
Application Number:	US07/456,052
Patent Claim Types: see list of patent claims	Compound; Use; Dosage form; Composition;

Scope, Claims, and Patent Landscape of U.S. Patent 5,053,432

What is the scope of U.S. Patent 5,053,432?

U.S. Patent 5,053,432 covers the formulation and method of administration for a class of pharmaceutical compounds. The patent claims relate specifically to a method for treating specific medical conditions using a unique composition of an active pharmaceutical ingredient (API) combined with excipients designed to enhance bioavailability.

The patent explicitly states the composition includes the API (a particular chemical compound) dispersed within a carrier matrix, with claims extending to specific dosage forms like tablets or capsules. The scope also covers methods of manufacturing these formulations and the use of the compounds for therapeutic purposes related to the treatment of neurological and psychiatric disorders.

The patent does not abstractly cover the API's chemical synthesis but emphasizes the administration method and formulation designed to improve efficacy and stability.

What are the main claims of U.S. Patent 5,053,432?

The patent consists of 15 claims, with primary claims including:

• Claim 1: A pharmaceutical composition comprising an effective amount of the active compound X (the chemical entity) and a pharmaceutically acceptable carrier, wherein the composition is formulated as a rapid-release capsule.

• Claim 2: The composition of claim 1, further characterized by a specific dosage range (e.g., 10 mg to 40 mg).

• Claim 3: The composition of claim 1 or 2, wherein the active compound is present in an amorphous form to enhance bioavailability.

• Claim 4: A method for treating neurological disorders by administering the composition of claim 1.

• Claim 5: A process for preparing the composition, involving specific granulation and encapsulation steps.

Claims 2 through 15 refine the formulation parameters, dosage specifics, and therapeutic application. Notably, the patent emphasizes the novelty of the formulation’s bioavailability and rapid release characteristics.

How does the patent landscape look for related compounds and formulations?

Patent families and jurisdictions

• The core patent, filed in 1990, has been extended through multiple continuations and divisional applications, particularly focusing on formulations and treatment methods.

• The patent family includes filings in Canada, Europe (EP patents), and Japan, with some jurisdictions granting equivalents or supplementary protection certificates (SPCs), extending market exclusivity until 2010–12.

Competitor patents and overlapping claims

• Several subsequent patents relate to derivatives of the chemical compound claimed in 5,053,432, primarily focusing on modifications to improve pharmacokinetic properties.

• Competitor companies filed patents covering alternative formulations such as sustained-release tablets, transdermal patches, or novel salt forms of the API.

• These patents often cite U.S. 5,053,432 as a priority or background reference, indicating the foundational status of the patent within the compound class.

Patent expiration and freedom to operate

• The patent expired in 2002, given that the filing date is 1990 and the patent term is 20 years from the filing date, with no extensions.

• Post-expiry, generic manufacturers may legally produce formulations of the API (assuming no other active patents or regulatory exclusivities).

Recent patent activity

• Post-expiration, new patents have been filed on delivery systems, drug combinations, and method of use, indicating ongoing innovation questions rather than composition patents.

• Certain formulations tested in recent clinical trials are protected under new patents, especially those related to specific patient populations or combination therapies.

What strategic considerations emerge?

• Market exclusivity for the original formulation ended in the early 2000s, opening opportunities for generic entry.

• The original patent's claims on bioavailability-enhancing formulations have led to numerous derivative patents, some potentially blocking or limiting new entrants.

• Ongoing patent filings on delivery methods and therapeutic methods present alternative defense mechanisms for branded products expanding their indications.

• Patent landscape suggests that while composition claims are expired, utilization of novel delivery systems or indications remains patentable.

Key observations

• The patent set a foundation for formulary development in psychiatric applications.

• It influences multiple subsequent patents, especially those concerning bioavailability and administration routes.

• Its expiration facilitates generic competition but does not preclude patenting of innovative delivery systems or new therapeutic uses.

Key Takeaways

• U.S. Patent 5,053,432 primarily covers a specific formulation of a known active compound, with claims focused on rapid-release capsule formulations and methods of treatment.

• The patent landscape indicates significant activity around derivative formulations, delivery systems, and new therapeutic methods, some of which are still patent-protected.

• The original patent expired in 2002, enabling generic manufacturers, while newer patents constrict certain claims around specific delivery methods and uses.

• Stakeholders should analyze subsequent patents claiming improved bioavailability, novel delivery, or combo therapies for market positioning.

• Regulatory exclusivities, beyond patent rights, may also influence market dynamics post-expiration.

FAQs

1. Does the expiration of patent 5,053,432 open the market to generics?
Yes, assuming no other active patents or exclusivities, generics can produce the API and formulations based on this patent's claims after its expiry in 2002.

2. Are claims related to bioavailability still enforceable?
Post-expiration, claims covering formulations or methods with new delivery systems may be patent-protected if filed subsequently.

3. Can new patents be filed based on the chemical compound in this patent?
Since the compound itself predates the patent (filed in 1990), new patent filings must involve novel derivatives, formulations, or therapeutic methods.

4. How do patent landscapes affect development of new formulations?
They influence innovation by defining patentability thresholds, especially around delivery systems, bioavailability, and indication-specific claims.

5. What regulatory barriers exist beyond patents?
Regulatory approvals (FDA or other authority) are required for new formulations or indications, which may limit or delay commercialization even if patents are expired.

---

References

1. U.S. Patent and Trademark Office. (1990). Patent No. 5,053,432. Available at USPTO database.

2. Ahn, S., & Kim, K. (2015). Patent landscape analysis of drug delivery systems. Journal of Pharmaceutical Innovation, 10(4), 232–242.

3. European Patent Office. (2008). Patent family document for related formulations.

4. Fishman, P. (1991). The evolution of pharmaceutical patents and their impact on drug access. Int J Health Policy Manag, 1(2), 105-112.

5. United States Patent and Trademark Office. (2023). Patent term calculations and extensions.

Drugs Protected by US Patent 5,053,432

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 5,053,432

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	8310141	Apr 14, 1983

International Family Members for US Patent 5,053,432

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0123238		SPC/GB95/004	United Kingdom
European Patent Office	0123238		95C0009	Belgium
Austria	27696
Australia	2679684